Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study

Writing Group (on behalf of the PHOSP-COVID Collaborative Group)†

Rachael A Evans* ¹, Olivia C Leavy ², Matthew Richardson ¹, Omer Elneima ¹, Hamish J C McAuley ¹, Aarti Shikotra ³, Amisha Singapuri ¹, Marco Sereno ¹, Ruth M Saunders ¹, Victoria C Harris ^{1,4}, Raminder Aul ⁵, Paul Beirne ⁶, Charlotte E Bolton ^{7,8,9}, Jeremy S Brown ¹⁰, Gourab Choudhury ^{11,12}, Nawar Diar Bakerly ^{13,14}, Nicholas Easom ^{15,16}, Carlos Echevarria ^{17,18}, Jonathan Fuld ^{19,20,21}, Nick Hart ²², John R Hurst ^{23,24}, Mark Jones ^{25,26}, Dhruv Parekh ^{27,28}, Paul Pfeffer ^{29,30}, Najib M Rahman ^{31,32,33,34}, Sarah Rowland-Jones ^{35,36}, Ajay M Shah ^{37,38}, Dan G Wootton ^{39,40,41}, Trudie Chalder ^{42,43}, Melanie J Davies ^{44,3,4}, Anthony De Soyza ^{45,46}, William Greenhalf ^{47,48,40}, Neil J Greening ¹, Liam G Heaney ^{49,50}, Simon Heller ⁵¹, Luke Howard ^{52,53}, Joseph Jacob ^{54,55}, R Gisli Jenkins ⁵⁶, Janet M Lord ^{57,58}, Will D-C Man ^{59,60}, Gerry P McCann ^{61,3}, Stefan Neubauer ^{62,63}, Peter JM Openshaw ⁵⁶, Joanna Porter ^{64,65}, Jennifer Quint ⁶⁰, Matthew J Rowland ⁶⁶, Janet T Scott ⁶⁷, Malcolm G Semple ^{68,69}, Sally J Singh ¹, Mark Toshner ^{70,21}, Keir Lewis ^{71,72,73}, Andrew Briggs ⁷⁴, Annemarie B Docherty ⁷⁵, Steven Kerr ^{76,75}, Nazir I Lone ^{77,78}, Aziz Sheikh ⁷⁷, Mathew Thorpe ⁷⁵, Bang Zheng ¹¹, James D Chalmers ⁷⁹, Ling-Pei Ho ⁸⁰, Alex Horsley ^{81,82}, Michael Marks ^{83,84,85}, Krisnah Poinasamy ⁸⁶, Betty Raman ^{87,88}, Ewen M Harrison ⁷⁵, Louise V Wain* ^{2,1}, Christopher E Brightling* ¹

*Joint first and last authors and contributed equally

†Details of the PHOSP-COVID Collaborative Group membership is provided as a supplementary file

Correspondence to: $Prof \Box Christopher \Box Brightling, \Box Institute for Lung Health, Department of Respiratory Sciences, NIHR Leicester <math>\Box BRC$, University of Leicester, Leicester, United Kingdom $\Box \underline{phosp@leicester.ac.uk}$

Funding □ Jointly funded by UK □ Research and Innovation and National Institute of Health Research (grant references: MR/V027859/1 and COV0319).

Ethics Approval ☐ Ethics Ref: 20/YH/0225 ☐

Author Institutions

- 1. The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK
- 2. Department of Health Sciences, University of Leicester, Leicester, UK
- 3. NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK
- 4. University Hospitals of Leicester NHS Trust, Leicester, UK
- 5. St Georges University Hospitals NHS Foundation Trust, London, UK
- 6. The Leeds Teaching Hospitals NHS Trust, Leeds, UK
- 7. University of Nottingham, Nottingham, UK
- 8. Nottingham University Hospitals NHS Trust, Nottingham, UK
- 9. NIHR Nottingham Biomedical Research Centre, Nottingham, UK
- 10. UCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, UK
- 11. University of Edinburgh, Edinburgh, UK
- 12. NHS Lothian, Edinburgh, UK
- 13. Manchester Metropolitan University, Manchester, UK
- 14. Salford Royal NHS Foundation Trust, Manchester, UK
- 15. Infection Research Group, Hull University Teaching Hospitals, Hull, UK
- 16. University of Hull, Hull, UK
- 17. The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
- 18. Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK
- 19. Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
- 20. University of Cambridge, Cambridge, UK
- 21. NIHR Cambridge Clinical Research Facility, Cambridge, UK
- 22. Lane Fox Respiratory Service, Guys and St Thomas NHS Foundation Trust, London, UK
- 23. University College London, London, UK
- 24. Royal Free London NHS Foundation Trust, London, UK
- 25. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
- 26. NIHR Southampton Biomedical Research Centre, University Hospitals Southampton, Southampton, UK
- 27. University of Birmingham, Birmingham, UK
- 28. University Hospital Birmingham NHS Foundation Trust, Birmingham, UK
- 29. Barts Health NHS Trust, London, UK
- 30. Queen Mary University of London, London, UK
- 31. Oxford University Hospitals NHS Trust, Oxford, UK
- 32. University of Oxford, Oxford, UK
- 33. Oxford NIHR Biomedical Research Centre, Oxford, UK
- 34. CAMS Oxford Institute, Oxford, UK
- 35. University of Sheffield, Sheffield, UK
- 36. Sheffield Teaching NHS Foundation Trust, Sheffield, UK
- 37. Kings College London, London, UK
- 38. Kings College London NHS Foundation Trust, London, UK
- 39. Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
- 40. Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
- 41. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK
- 42. Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK
- 43. South London and Maudsley NHS Trust, London, UK
- 44. Diabetes Research Centre, University of Leicester, Leicester, UK
- 45. Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK
- 46. Newcastle upon Tyne Teaching Hospitals Trust, Newcastle upon Tyne, UK
- 47. University of Liverpool, Liverpool, UK
- 48. The CRUK Liverpool Experimental Cancer Medicine Centre, Liverpool, UK
- 49. Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, UK
- 50. Belfast Health & Social Care Trust, Belfast, UK

- 51. Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
- 52. Imperial College Healthcare NHS Trust, London, UK
- 53. Imperial College London, London, UK
- 54. Centre for Medical Image Computing, University College London, London, UK
- 55. Lungs for Living Research Centre, University College London, London, UK
- 56. National Heart and Lung Institute, Imperial College London, London, UK
- 57. MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
- 58. NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham and the University of Birmingham, Birmingham, UK
- 59. Royal Brompton and Harefield Clinical Group, Guys and St Thomas NHS Foundation Trust, London, UK
- 60. NHLI, Imperial College London, London, UK
- 61. Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
- 62. Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- 63. NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
- 64. UCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, UK
- 65. ILD Service, University College London Hospital, London, UK
- 66. Kadoorie Centre for Critical Care Research, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK
- 67. MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
- 68. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection,

Veterinary and Ecological Sciences, University of Liverpool, UK

- 69. Respiratory Medicine, Alder Hey Childrens Hospital, Liverpool, UK
- 70. Cambridge NIHR BRC, Cambridge, UK
- 71. Hywel Dda University Health Board, Wales, UK
- 72. University of Swansea, Wales, UK
- 73. Respiratory Innovation Wales, Wales, UK
- 74. London School of Hygiene & Tropical Medicine, London, UK
- 75. Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK
- 76. Roslin Institute, University of Edinburgh, Edinburgh, UK
- 77. Usher Institute, University of Edinburgh, Edinburgh, UK
- 78. Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK
- 79. University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
- 80. MRC Human Immunology Unit, University of Oxford, Oxford, UK
- 81. Division of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
- 82. Manchester University NHS Foundation Trust, Manchester, UK
- 83. Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK
- 84. Hospital for Tropical Diseases, University College London Hospital, London, UK
- 85. Division of Infection and Immunity, University College London, London, UK
- 86. Asthma UK and British Lung Foundation, London, UK
- 87. Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- 88. Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Summary

Background

There are currently no effective pharmacological or non-pharmacological interventions for Long-COVID. To identify potential therapeutic targets, we focussed on previously described four recovery clusters five months after hospital discharge, their underlying inflammatory profiles and relationship with clinical outcomes at one year.

Methods

PHOSP-COVID is a prospective longitudinal cohort study, recruiting adults hospitalised with COVID-19 across the UK. Recovery was assessed using patient reported outcomes measures (PROMs), physical performance, and organ function at five-months and one-year after hospital discharge. Hierarchical logistic regression modelling was performed for patient-perceived recovery at one-year. Cluster analysis was performed using clustering large applications (CLARA) k-medoids approach using clinical outcomes at five-months. Inflammatory protein profiling from plasma at the five-month visit was performed.

Findings

2320 participants have been assessed at five months after discharge and 807 participants have completed both five-month and one-year visits. Of these, 35·6% were female, mean age 58·7 (SD 12·5) years, and 27·8% received invasive mechanical ventilation (IMV). The proportion of patients reporting full recovery was unchanged between five months 501/1965 (25·5%) and one year 232/804 (28·9%). Factors associated with being less likely to report full recovery at one year were: female sex OR 0·68 (95% CI 0·46-0·99), obesity OR 0·50 (95% CI 0·34-0·74) and IMV OR 0·42 (95% CI 0·23-0·76).

Cluster analysis (n=1636) corroborated the previously reported four clusters: 'very severe', 'severe', 'moderate/cognitive', 'mild' relating to the severity of physical, mental health and cognitive impairments at five months in a larger sample. There was elevation of

4

inflammatory mediators of tissue damage and repair in both the 'very severe' and the

'moderate/cognitive' clusters compared to the 'mild' cluster including interleukin-6 which was

elevated in both comparisons. Overall, there was a substantial deficit in median (IQR) EQ5D-

5L utility index from pre-COVID (retrospective assessment) 0.88 (0.74-1.00), five months

0.74 (0.60-0.88) to one year: 0.74 (0.59-0.88), with minimal improvements across all

outcome measures at one-year after discharge in the whole cohort and within each of the four

clusters.

<u>Interpretation</u>

The sequelae of a hospital admission with COVID-19 remain substantial one year after

discharge across a range of health domains with the minority in our cohort feeling fully

recovered. Patient perceived health-related quality of life remains reduced at one year

compared to pre-hospital admission. Systematic inflammation and obesity are potential

5

treatable traits that warrant further investigation in clinical trials.

Funding UKRI & NIHR

Research in Context

Evidence before this study

We systematically searched PubMed and Embase databases for large studies reporting one-year follow-up data for hospitalised COVID-19 patients published between January 1, 2021 and November 7, 2021, without language restrictions. Search terms related to COVID-19, hospitalisation and long-term follow-up were used. A large prospective cohort study from Wuhan, China (n = 1276) showed that 49% of patients reported at least one persistent symptom during a follow-up clinic visit at 12 months post COVID-19; no significant improvement in exercise capacity was observed between 6- and 12-month visits. Another two large cohort studies in China (n = 2433) and Spain (n = 1950) with one-year follow-up data from telephone interviews showed that 45% and 81% of patients reported at least one residual COVID-19 symptom, respectively. However, no previous studies have compared the trajectories of COVID-19 recovery in patients classified by different clinical phenotypes, and there are no large studies investigating the relationship between systemic inflammation and ongoing health impairments post COVID-19.

Added value of this study

In a diverse population of adults post-hospital admission with COVID-19, our large UK prospective multi-centre study reports several novel findings: the minority felt fully recovered at one year with minimal recovery from five months across any health domain; female sex and obesity are associated with being less likely to feel fully recovered at one year; several inflammatory mediators were increased in individuals with the most severe physical, mental health, and cognitive impairments compared to individuals with milder ongoing impairments.

6

<u>Implications of all the available evidence</u>

Both pharmacological and non-pharmacological interventions are urgently needed to improve the ongoing burden following hospitalisation for COVID-19 both for individuals and healthcare systems; our findings support the use of a precision medicine approach with potential treatable traits of systemic inflammation and obesity.

7

Introduction

To date (December, 2021), there have been over 260 million cases of SARS-CoV-2 reported

worldwide, 10 million cases in the UK² and over half a million patients in the UK admitted

to hospital for COVID-19. We, and others, have shown that this sizeable population are at

high risk of persisting health impairments six months after discharge associated with reduced

physical function and health-related quality of life.³⁻⁴ It is essential to understand the longer-

term trajectory of recovery to identify ongoing healthcare needs, and the required response by

healthcare systems and policy makers for this already large and ever-increasing population.

Much remains unknown about the longer-term sequelae of COVID-19. In the largest cohort

study to date from Wuhan, China, nearly half of patients experienced persistent symptoms 12

months post-discharge from hospital for COVID-19.⁵ Between six- and 12-months post-

8

discharge, there was no change in six-minute walk distance, but some improvement in the

results of pulmonary imaging.⁵

The mechanisms underlying long-term persistence of symptoms are currently unknown. A

potential hypothesis is that the hyperinflammation associated with acute COVID-19 leads to a

persistent inflammatory state post COVID-19, associated with dysregulated immunity and

multiorgan dysfunction. Although multiple studies have highlighted elevated inflammatory

markers, including IL-6, associated with severity of acute illness, ^{6,7} there are no large studies

investigating the relationship between systemic inflammation and ongoing health

impairments after COVID-19.

Currently, there are no effective treatments for Long-COVID/ post-COVID-19 condition.

Long-COVID is defined by National Institute for Health and Care Excellence (NICE) as on-

going symptoms beyond four to 12 weeks after COVID-19 and post-COVID-19 condition by the World Health Organisation as "occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis"). 8,9 Improved characterisation of this population with an emphasis on elucidating underlying mechanisms is needed to identify potential therapeutic targets. We previously described four clinical recovery clusters of patients: 'very severe', 'severe', 'moderate/cognitive', and 'mild' defined by severity of ongoing physical, mental health and cognitive impairment five months after a hospital admission with COVID-19. In this report, using the ongoing PHOSP-COVID longitudinal study cohort, we sought to determine patient-perceived recovery, the associated risk factors for failure to recover at one year after discharge, and to investigate the association between our previously described clusters and multiple inflammatory mediators using a proteomics panel. We report the trajectory of recovery at one year across different health domains and the differences in recovery trajectory by cluster.

Methods

Study design and participants

The PHOSP-COVID cohort recruitment strategy including eligibility criteria has been

described previously.³ In brief, we recruited patients aged 18 years and older who were

discharged from over 50 National Health Service (NHS) hospitals across the four UK nations

following admission to a medical assessment unit or ward for confirmed or clinician-

diagnosed COVID-19 before March 31, 2021. The current analysis involves participants who

consented to attend two additional in-person research visits (Tier 2 – see protocol and Table

S1) within one-year after discharge alongside routine clinical care.

Written informed consent was obtained from all study participants. The study was approved

by the Leeds West Research Ethics Committee (20/YH/0225) and is registered on the

ISRCTN Registry (ISRCTN10980107).

Procedures

Participants were invited to attend research visits at two to seven months post-discharge

('five-month visit') and at 10 to 14 months ('one-year visit'). Participants were also able to

attend a one-year only visit if they were outside the time period for a five-month visit at the

time of consent and were discharged before November 30, 2020. The core set of data

variables collected at each visit and included in this study are listed in the Supplementary

materials, Table S2. These included baseline demographics, information about disease

severity and treatment during their hospital admission, as well as physical tests, patient

reported outcome measures (PROMs), pulmonary physiology and blood test results obtained

at their clinical and research visits (see Supplementary methods). Patients were also asked to

complete the EQ5D-5L, Washington Group Short Set Functioning (WGSS) and Visual

10

analogue scale for Breathlessness and Fatigue retrospectively to assess their perceived pre-COVID health (Supplementary Table S2). Plasma samples obtained at the five-month visit were analysed using the Olink Explore 384 Inflammation panel. Sample processing and assay

details are provided in the Supplementary methods.

The primary outcome for this analysis was patient-perceived recovery assessed using a study-specific questionnaire and the question 'Do you feel fully recovered?' and participants could answer 'Yes', 'No', or 'Not sure'. Other outcomes included symptoms since their COVID-19 hospital admission included collected on the bespoke study-specific questionnaire, validated patient reported outcome questionnaires, and physiological measures (including physical performance and spirometry). See Supplementary Tables S1 and S2 for details of all variables included in this study.

Statistical analysis

Continuous variables were presented as median and interquartile range (IQR) or mean and standard deviation (SD). Binary and categorical variables were presented as counts and percentages (by row or by column as indicated in table legends). Participants were stratified by patient-perceived recovery: Yes (recovered), No (not recovered), or Not sure.

Missing data were reported within each variable and per category. Within visit, a chi-squared test was used to identify differences in proportions across multiple categories. For normally distributed and non-normally distributed continuous data, analysis of variance (ANOVA F-test) and Kruskal Wallis tests respectively, were used to test differences across categories. For paired data between the five-month and one-year visit, a McNemar's Chi-squared test with continuity correction and a McNemar's Chi-squared test were used for binary variables

11

and variables with > 2 levels, respectively. For normally distributed and non-normally

distributed continuous data, a paired t-test and a Wilcoxon signed-rank test were used,

respectively.

As previously described³, univariable and hierarchical multivariable logistic regression

models (admission hospital included as random effect) were used to explore risk factors

associated with patient-perceived recovery. Missing data was addressed using multiple

imputation (10 datasets, 10 iterations, final models combined using Rubin's Rules), with the

outcome used in imputation models, but not itself imputed.

In order to evaluate any potential bias arising due to loss to follow-up in participants

attending the one-year visit, we compared characteristics and patient-perceived recovery

(measured at five-months) in attendees and non-attendees, restricted to participants

discharged between February 01, 2020 and 30 June, 2020. This was because this group had

completed at least 14 months of follow-up at the time of analysis (October 6, 2021), allowing

an additional month for completing data entry. We also compared characteristics between

those attending five-month, one-year and both visits to understand if there were any

systematic differences between these groups.

In this larger cohort, we repeated our previous unsupervised cluster analysis³ of patient

12

recovery measured using symptom questionnaires (PROMS), physical performance and

cognitive assessment data (Questionnaires: Dyspnoea-12, Fatigue - the Functional

Assessment of Chronic Illness therapy (FACIT), Generalised Anxiety Disorder (GAD-7),

Patient Health Questionnaire (PHQ-9), Post-Traumatic Stress Disorder Checklist for DSM-5

(PCL-5), Short Physical Performance Battery (SPPB) and Montreal Cognitive Assessment

(MoCA) as continuous variables) from the five-month visit (discharge dates Feb 2020 –

March 2021) using the clustering large applications (CLARA) k-medoids approach 10. Scores

were centred, normalised and transformed so higher burden of disease represented higher

values. A Euclidean distance metric was used, and the optimal number of clusters chosen

using a silhouette plot. Cluster membership was determined for each individual using five-

month visit data. Characteristics at one-year and change in characteristics between five-

months and 12-months, are presented as cluster-stratified tables. All tests were two-tailed and

p values <0.05 were considered statistically significant. We did not adjust for multiple

testing.

Plasma protein levels were compared between clusters using the mildest recovery cluster as

baseline and using multinomial regression with age, body mass index (BMI) and number of

comorbidities as covariates (see Supplementary Methods). Significance was defined as p <0.1

after False Discovery Rate adjustment for multiple testing.

We used R (version 3.6.3) with the finalfit, tidyverse, mice, cluster, ggplot2, ggalluvial,

13

radiant, dabestr and recipes packages.

Results

At the time of analysis October 6 2021, 2320 participants (discharged from hospital March 7, 2020 to April 18, 2021) had attended a five-month visit (median [IQR] 5 [4-6] months post-discharge), 924 participants (discharged February 28, 2020 to November 28, 2020) had returned for a one-year visit (13 [12-13]) months post-discharge) and 807 participants had attended both visits (Figure 1). The individual and hospital admission characteristics including severity of acute illness between those with a five-month visit, one-year visit, and those who attended both visits were similar (Table 1) except for acute treatment with corticosteroids. 350/1063 (32.9%) of participants discharged between February 01, 2020 and June 30, 2020 had either not attended or not had data entered for a one-year visit at the time of analysis. Age, BMI, co-morbidities, the proportion requiring invasive mechanical ventilation and five-month recovery status were similar between those who had and had not attended (Tables S3a and S3b).

Overall, 25.5% (501/1965) of patients felt fully recovered at five-months post-discharge, and 28.9% (232/804) at one year (Figure 2a, Table S10b) with similar proportions observed in those with paired data (Table 2b). Assuming all the participants who had missing data at one year had either not recovered or fully recovered, the adjusted proportion of participants feeling fully recovered at one year is 212/1063 (19.9%) or 604/1063 (60.2%), respectively (Table 3b). The proportions that reported feeling fully recovered excluding or including those not yet due a one-year visit and missing data are shown in Figure S2a and b, respectively. In multivariable analysis, female sex (OR 0.68 (0.46-0.99)), Body Mass Index (BMI) 30 kg/m² or greater (OR 0.50 (0.34-0.74)) and receiving invasive mechanical ventilation (IMV) World Health Organisation [WHO] category 7-9 (OR 0.42 (0.23-0.76)) were all independent factors associated with being less likely to recover at one-year (Figure

2b and Table S4). There was no effect of receiving systemic corticosteroids (OR 1.05 (0.66-1.65)) during the acute admission on patient-perceived recovery at one-year for the whole cohort (Figure 2b, Table S4). There was also no effect of time from discharge to the research visit (OR 1.00 (1.00-1.01), p=0.118)).

For the current five-month dataset with complete data n=1636 (Figure 1), the previously identified four clusters³ were confirmed representing 'very severe' physical and mental health impairment (n=319), 'severe' physical and mental health impairment (n=493), 'moderate' physical health impairment with cognitive impairment (n=179) and 'mild' mental and physical health impairment (n=645) (Table S5, Figure S2). 86·7% (664/766) of individuals included in the previous study³ were re-assigned to the same recovery cluster as before; the cognitive cluster had the most assignment alterations (60/127). Characteristics of individuals in each recovery cluster are shown in Table S6. The very severe cluster had a higher proportion of female sex (165/306, 53.9%) and obesity (204/288, 70.8%) compared to the 'mild' cluster (177/624, 28.4%) and (288/568, 50.2%), respectively.

After quality control, plasma proteome data for 296 protein features and complete clinical data for cluster assignment were available at five-months for 626 participants: 'very severe' cluster n=111, 'severe' cluster n=173, 'moderate/cognitive' cluster n=73 and 'mild' cluster n=269. Age, BMI, and two or more co-morbidities were associated with cluster membership whereas receiving IMV during the acute illness was not (analysis in participants with plasma proteome data and a cluster assignment) (Table S7). After adjustment for age, BMI, and co-morbidity count, 13 proteins were significantly elevated in participants in the 'very severe' recovery cluster compared to those in the 'mild' cluster (Table S8, Figure 3). These were Trefoil Factor 2 (TFF2), Transforming Growth Factor Alpha (TGFA), Lysosomal Associated

Membrane Protein 3 (LAMP3), CD83 molecule (CD83), Galectin-9 (LGALS9), Plasminogen Activator, Urokinase Receptor (PLAUR), Interleukin 6 (IL6), Erythropoietin (EPO), Fms Related Receptor Tyrosine Kinase 3 Ligand (FLT3LG), Agrin (AGRN), Secretoglobin Family 3A Member 2 (SCGB3A2), Follistatin (FST) and C-Type Lectin Domain Family 4 Member D (CLEC4D) (Figure S4). In addition, IL6 and CD70 Molecule (CD70) were significantly increased in the 'moderate/cognitive' recovery cluster compared to the 'mild' cluster.

The top 10 most common persistent symptoms at one-year post-discharge were fatigue (463/770, 60.1%), aching muscles (442/809, 54.6%), physical slowing down (429/811,52.9%), poor sleep (402/769, 52.3%), breathlessness (395/769, 51.4%), joint pain or swelling (382/803, 47.6%), slowing down in thinking (377/808, 46.7%), pain (359/770, 46.6%), short term memory loss (360/808, 44.6%) and limb weakness (341/813, 41.9%) (Table S9). Overall, these were essentially unchanged in prevalence from five months to one year, with small reductions in rates of limb weakness (47.6% at five-months vs. 41.7% at one-year, p=0.010), paraesthesia (40.6% vs. 35.2%, p=0.014) and balance problems (34.9% vs. 30.0, p=0.008). There was either no or minimal improvement in PROMS, physical function, cognitive impairment, or organ function at one-year compared to five-months post-discharge (paired data Table 2b and presented by patient-perceived recovery in Tables S10a and b). At one year, 147/684 (21.5%) and 169/680 (24.9%) participants had clinically relevant symptoms of anxiety and/or depression, respectively, 68/680 (10.0%) had symptoms compatible with post-traumatic stress disorder, and 55/623 (8.8%) had significant cognitive impairment (Table 2b). Measures of symptoms and physical function were significantly different across participants feeling fully recovered, not sure, or not fully recovered at five months and one-year but cognitive impairment and measures of organ function (except for

Forced Vital Capacity [FVC]) were not (Table 2b). Similarly, health-related quality of life was significantly different across participants reporting being fully recovered, not sure or not recovered at both five months, and one year (Figure 2d and Tables S10a and b).

In addition to higher proportions of female sex and obesity (Table S6), the more severe clusters were associated with lower proportion of feeling fully recovered 11/272 (4.0%) vs. 90/179 (50.3%) (Figure 2c), reduced exercise capacity ISWT 44.4% predicted vs. 72.4% predicted, higher number of symptoms 20 vs 4, and higher proportion of elevated CRP level >5mg/L 38.4% vs. 14.5% compared to the mild cluster (Table 3, Figure S3). A comparison of health outcomes across the four clusters between the five-month and one-year time-points (n=602) shows there was minimal change across the two time-points for the four clusters (Table 3). In the very severe cluster, symptoms of anxiety, depression, breathlessness and fatigue significantly improved between five-months and one-year, but with minimal change in physical performance and no overall change in systemic inflammation measured by CRP levels. Cognitive impairment significantly improved at one-year in the moderate 'cognitive cluster and showed a non-significant trend towards improvement in the severe cluster but was unchanged in the other clusters (Table 3). Compared with patient perceived pre-COVID-19 health, decrements were seen at five months and sustained at one-year across health-related quality of life (EQ5D-5L), disability (WG-SS-SCo), and severity of breathlessness and fatigue experienced in the last 24 hrs (Figure 3, Table S11, Figure S5).

Discussion

In a diverse UK population of adult survivors of COVID-19, we found the minority of participants felt fully recovered one year after hospital discharge with minimal improvement after their five-month assessment. The most common ongoing symptoms were fatigue, muscle pain, physically slowing down, poor sleep and breathlessness. The major risk factors for failure to recover at one-year were female sex, obesity and receiving IMV during the acute illness. There were substantial impairments in health-related quality of life (HRQoL) at five-months and one-year compared to retrospective self-reported pre-infection levels. Cluster analysis using the participants' five-month assessment corroborated four different clusters: 'very severe', 'severe', 'moderate/cognitive', and 'mild' based on the severity of physical, mental and cognitive impairments with similar characteristics to previously reported³. We confirmed that obesity, reduced exercise capacity, a higher number of symptoms and elevated serum CRP level were associated with the more severe clusters³. In the largest post-hospital cohort with systemic inflammatory profiling to date, inflammatory mediators consistent with persistent lung and systemic inflammation were elevated between both the 'very severe' and 'moderate/cognitive' clusters, and the mild cluster. We therefore highlight traits to identify individuals at high risk of non-recovery and potential targetable pathways for interventions.

Comparing the systemic inflammatory profiling at five months after discharge between the 'very severe' and 'mild' cluster, the most elevated protein, TTF2, is a protein released with mucin from mucosal epithelium including lung and gastric mucosa. It has postulated roles in repair of damaged epithelium¹¹ and in combination with IFN-kappa reduced duration of infection in a small open-label randomised controlled trial of acute COVID-19.¹¹ In a previous study of patients during acute illness with COVID-19 using Olink proteomics, IL-6

was the most upregulated protein at day seven amongst patients who developed ARDS and subsequently died.⁶ Similarly, other proteins we identified such as LAMP3, Gal-9, CD83 are involved in T-cell macrophage and dendritic cell activation and were associated with increased morbidity and mortality during acute COVID-19 infection. 12-14 These changes suggest persistent mucosal epithelial abnormalities and inflammatory cell activation. Elevated serum levels of the C-terminal fragment of Agrin have been reported in older adults with sarcopenia, possibly related to break down of the neuromuscular junction. ¹⁵ The raised Agrin levels seen here may therefore contribute to the high prevalence of physical impairment. Interestingly, in the 'moderate/cognitive' cluster versus the 'mild' cluster IL6 and CD70 were elevated suggesting possible neuroinflammation contributing to the cognitive impairment as CD70 has been implicated in inflammation in the Central Nervous System (CNS)¹⁶ via a role in differentiation of proinflammatory pathogenic lymphocytes. There were small improvements in cognition in the 'moderate/cognitive' cluster and a trend towards improvement in the 'very severe' clusters indicating that some of this deficit was not preexisting and potentially modifiable; however, considerable deficit persisted at one year. The associations with the inflammatory mediators remained after adjusting for age, BMI and comorbidities, and the proportion having received invasive mechanical ventilation was similar across the clusters; all factors known to be associated with systemic inflammation¹⁷. Taken together, the elevated mediators provide biological plausibility for the persistent severe impairments seen in physical, mental health and cognitive impairment after COVID-19.

The limited recovery from five-months to one-year post-hospitalisation in our study across symptoms, mental health, exercise capacity, organ impairment and quality-of-life is striking. There are limited similar detailed prospective longitudinal studies for patients hospitalised with COVID-19 but in a larger cohort we confirm their findings of minimal recovery. ¹⁸⁻²⁰

Although the large-scale study from Wuhan, China suggests a greater magnitude of recovery, new onset symptoms persisted in half of the patients.⁵ Notably, the Wuhan cohort included less severe acute illness with only 1% requiring IMV and 7% requiring high flow nasal oxygen and/or continuous positive airway pressure (CPAP), had fewer pre-existing comorbidities, and a higher proportion of never-smokers. In non-COVID related ARDS survivors, little recovery in health-related quality of life is observed beyond six months, but larger improvements in walking distance^{21,22} than we report post-COVID-19 in our cohort where over 70% did not receive IMV. In non-hospitalised patients after COVID-19 the proportion that develop Long-COVID appears lower.^{23,24}

The responses for patient perceived recovery were discriminatory across all the PROMS and exercise measures providing additional validity for this outcome measure. We found female sex and obesity were major risk factors for not recovering at one year confirming existing results from smaller cohorts²⁵, and non-hospitalised cohorts.²⁶⁻²⁸ Female sex was similarly associated with worse recovery for fatigue, mental health and lung function at 12 months in the Wuhan cohort.⁵ In our clusters, female sex and obesity were also associated with more severe ongoing health impairments including reduced exercise performance and HRQoL at one year, potentially highlighting a group which may need higher intensity interventions such as supervised rehabilitation. Health-related quality of life pre-COVID was substantially greater than at five-months post-discharge across all four clusters indicating that the persistent burden of impaired physical and mental health is not simply explained by pre-existing morbidity. The total number and range of ongoing symptoms at one year was striking, positively associated with the severity of Long-COVID, and emphasises the multisystem nature of Long-COVID. Other studies have shown the number of symptoms during the acute illness were associated with the likelihood of developing Long-COVID.²⁹ Whether

the number of ongoing symptoms, a simple widely available measure, could underpin a future risk score deserves further attention. We suggest that female sex and obesity should be considered when planning follow-up healthcare services.

Currently, there are no specific therapeutics for Long-COVID and our data highlights effective interventions are urgently required. Critically, our findings of persistent systemic inflammation, particularly in those in the 'very severe' and 'moderate/cognitive' clusters, suggests these groups might respond to anti-inflammatory strategies. The upregulation of IL6 suggests that anti-IL6 biologics that were successful for acute-hospitalised COVID-19³⁰ might also have a place in Long-COVID. Similarly, activation of the uPAR pathway suggests that IL1 activation might play a role, with soluble uPAR a biomarker in acute COVID-19 associated with good response to the recombinant IL-1 receptor antagonist anakinra.31 Impaired exercise capacity was also associated with the more severe clusters and showed minimal improvement at one-year (well below the minimum clinically important distance for other long-term conditions). 32-34 Current therapies available for some adults with Long-COVID include rehabilitation, 35 but the optimal exercise prescription is contentious due to concerns of post-exertional symptom exacerbation (PESE). Our data confirm high prevalence of musculoskeletal symptoms including muscle ache, fatigue, breathlessness, physically slowing down, and limb weakness.^{5,16} This supports the need to investigate rehabilitation in combination with other therapies to improve skeletal muscle function such as mitochondrial energetics, mitophagy enhancers and drugs to combat cell senescence (associated with ageing).

The concordance of the severity of physical and mental health impairment in Long-COVID highlights the need for close integration between physical and mental healthcare for Long-

21

COVID including assessment and interventions, but also for healthcare professional knowledge transfer to improve patient care. It also suggests the need for complex interventions that target both physical and mental health impairments in order to ameliorate symptoms. However, specific therapeutic approaches to manage post-traumatic stress disorder may be needed.³⁶ With obesity being associated with both non-recovery and severity of Long-COVID, whether weight reduction using pharmacological and non-pharmacological approaches in concert can ameliorate Long-COVID warrants further investigation. Beyond diet and lifestyle interventions, glucagon like peptide-1 (GLP-1) analogues have recently been reported to achieve clinically important weight reduction.³⁷

Our cohort study is ongoing, and we report these one-year findings to add novel findings to the limited literature, help direct clinical care and further investigation. However, there are limitations. There will be selection bias for participants returning for a one-year visit, although we have not found overt differences between the demographics, or five-month recovery status between attendees and non-attendees of the one-year visit. Notwithstanding this limitation, even with the assumption of all participants with missing data having fully recovered then the highest estimate is 60% of participants feeling fully recovered at one year demonstrating a substantial proportion with ongoing new morbidity. Our cohort has a higher proportion of patients requiring IMV than typically seen in UK hospitals³⁸ and therefore our results may not be directly generalisable to the wider population. To reduce uncertainty of the impact of pre-existing illness, we asked our recruits whether they felt fully recovered i.e., back to their normal. We also asked them retrospectively to estimate their pre-COVID-19 health status including the most prevalent symptoms, disability and health-related quality of life; we recognise there might be recall bias. Data linkage to electronic patient records is in process, but not currently available so in the current report pre-existing co-morbidities were

self-reported and data regarding hospital admissions and mortality in the first year are unavailable. Our study suggests that persistent inflammation may be underlying ongoing impairment in some participants; the specific mechanisms underlying this signal require further investigation and replication. We describe several associations with more severe health impairments at one year. Our findings cannot confirm causality but suggest these associations should be further investigated as part of mechanistic studies and clinical trials.

In summary, our study highlights an urgent need for healthcare services to support this large and rapidly increasing patient population where, in our cohort, there is a substantial burden of symptoms, reduced exercise capacity and large decrements in health-related quality of life after one year. Without effective treatments, Long-COVID has the potential to become a highly prevalent new long-term condition. Our study also provides a rationale for investigating treatments for Long-COVID with a precision medicine approach to target treatments to the relevant phenotype, potentially anti-inflammatories, weight reduction and rehabilitation to restore health-related quality of life.

23

Contributors

The manuscript was initially drafted by CEB, RAE, LVW further developed by the writing committee. CEB, RAE, LVW, OE, HJCM, AShi, ASi, MJD, ABD, NIL, AShe, JDC, L-PH, AH, MM, KP, BR, made substantial contributions to the conception and design of the work. RAE, ASi, MS, RMS, VCH, RA, PB, CEBo, JSB, GC, NDB, NE, CE, JF, NH, JRH, MJ, DP, PP, NMR, SR-J, AMS, DGW, JDC, L-PH, AH, MM, WD-CM made substantial contributions to the acquisition of data. CEB, RAE, LVW, OCL, MR, OE, HJCM, MS, TC, MJD, ADS, WG, NJG, LGH, SH, LH, JJ, RGJ, JML, WD-CM, GPM, SN, PJMO, JP, JQ, MJR, JTS, MGS, SJS, MTo, KL, AB, ABD, SK, NIL, AShe, MTh, BZ, JDC, L-PH, AH, MM, KP, BR, EMH, made contributions to the analysis, or interpretation of data for the work. All authors contributed to data interpretation and critical review and revision of the manuscript. Final approval of the version to be published and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Acknowledgments

This study would not be possible without all the participants who have given their time and support. We thank all the participants and their families. We thank the many research administrators, health-care and social-care professionals who contributed to setting up and delivering the study at all of the 69 NHS Trusts and 25 Research Institutions across the UK as well as all the supporting staff at the At the NIHR Clinical Research Network, Health Research Authority, Research Ethics Committee, Department of Health and Social Care Public Health Scotland, Public Health England and support from the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C). At the NIHR Office for Clinical Research Infrastructure (NOCRI) we thank Kate Holmes (for her support in coordinating the charities group) Ivana Poparic and Peter Sargent and Sheuli Porkess at the Association of the British Pharmaceutical Industry for their advice in commercial discussions. We are very grateful to all the charities that have provided insight to the study- Action Pulmonary Fibrosis, Alzheimer's Research UK, Asthma UK /British Lung Foundation UK/BLF, British Heart Foundation, Diabetes UK, Cystic Fibrosis Trust, Kidney Research UK, MQ Mental Health, Muscular Dystrophy UK, Stroke Association Blood Cancer UK, McPin Foundations, Versus Arthritis. We thank the NIHR Leicester Biomedical Research Centre patient and public involvement group and the Long Covid Support Group.

Data sharing □

The \square protocol, consent form, definition and \square derivation \square of clinical characteristics and outcomes, training materials, regulatory documents, requests for data access and other relevant study materials are available online at \square www.phosp.org.

Funding

PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the □ Department of Health and Social Care through the National Institute for Health Research (NIHR) □ rapid response panel to tackle COVID-19 (grant references: MR/V027859/1 and COV0319). □ Core funding was provided by □ NIHR Leicester Biomedical Research Centre to

support the PHOSP-COVID coordination team and NIHR Biomedical Research Centres (BRCs), Clinical Research Facilities (CRF) and NIHR Health Protection Research Unit (HPRU) and Translational Research Collaborations (TRCs) network across the country. The institutional funding that supports the outbreak labs that process the PHOSP samples NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE) and Liverpool Experimental Cancer Medicine Centre (grant reference: C18616/A25153)

ABD is funded by a Wellcome Trust grant (216606/Z/19/Z)

RAE* holds a National Institute for Health Research (NIHR) clinician scientist fellowship (CS-2016-16-020). NJG holds a NIHR post-doctoral fellowship (PDF \(\) 2017 \(\) 10 \(\) 052).

JJ was supported by a Wellcome Trust Clinical Research Career Development Fellowship 209553/Z/17/Z] and by the NIHR University College London Hospital Biomedical Research Centre, UK.

LVW* was supported by a GSK / British Lung Foundation Chair in Respiratory Research (C17-1)

Funder role

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NIHR or the Department of Health and Social Care. ☐No form of payment was given to anyone to produce the manuscript. All members of the writing group have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Ethics Approval Ethics Ref: 20/YH/0225 Trial ID: ISRCTN10980107

References

- 1. Coronavirus Resource Centre John Hopkins University. https://coronavirus.jhu.edu/map.html. Accessed 6 December 2021
- 2. UK summary coronavirus (COVID-19) in the UK. https://coronavirus.data.gov.uk. Accessed 6 December 2021
- 3. Evans RA, McAuley H, Harrison EM et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. *Lancet Respir Med.* 2021 Nov; **9**(11):1275-1287
- 4. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021; **397**(10270):220-232.
- 5. Huang L, Yao Q, Gu X et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. *Lancet* 2021; **398**(10302):747-758.
- 6. Filbin MR, Mehta A, Schneider AM, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. *Cell Rep Med.* 2021; **2**(5):100287.
- 7. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol. 2021; 6(57):eabg9873.
- 8. COVID-19 rapid guideline: managing the long-term effects of COVID-19: https://www.nice.org.uk/guidance/ng188, updated November, 2021. Accessed 12.12.2021
- 9. A clinical case definition of post COVID-19 condition by a Delphi consensus https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1_6_October_2021_. Accessed 12.12.2021
- 10. Kaufman L, Rousseeuw PJ. Clustering large applications (Program CLARA). *Finding groups in data: an introduction to cluster analysis* 2008: 126-63.
- 11. Fu W, Liu Y, Liu L, et al. An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19.

 EClinical Medicine. 2020;27:100547.
- 12. Tserel L, Jõgi P, Naaber P, et al. Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals. ☐ *Front Immunol*. 2021;12:709759.
- 13. Fraser DD, Patterson EK, Slessarev M, et al. Endothelial Injury and Glycocalyx Degradation in Critically Ill Coronavirus Disease 2019 Patients: Implications for Microvascular Platelet Aggregation. ☐ *Crit Care Explor*. 2020;2(9):e0194.
- 14. Laudanski K, Jihane H, Antalosky B, et al. Unbiased Analysis of Temporal Changes in Immune Serum Markers in Acute COVID-19 Infection With Emphasis on Organ Failure, Anti-Viral Treatment, and Demographic Characteristics. [Front Immunol. 2021;12:650465.]

- 15. Hettwer S, Dahinden P, Kucsera S, et al. Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients. *Exp Gerontol*. 2013;48(1):69-75.
- 16. Dhaeze, T., Tremblay, L., Lachance, C. *et al.* CD70 defines a subset of proinflammatory and CNS-pathogenic T_H1/T_H17 lymphocytes and is overexpressed in multiple sclerosis. *Cell Mol Immunol* **16**, 652–665 (2019)
- 17. Griffith DM, Vale ME, Campbell C, Lewis S, Walsh TS. Persistent inflammation and recovery after intensive care: A systematic review. *J Crit Care*. 2016;33:192-199.
- 18. Fernández-de-Las-Peñas C, Guijarro C, Plaza-Canteli S, Hernández-Barrera V, Torres-Macho J. Prevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study. *Lung*. 2021;199(3):249-253.
- 19. Maestre-Muñiz MM, Arias Á, Mata-Vázquez E, et al. Long-Term Outcomes of Patients with Coronavirus Disease 2019 at One Year after Hospital Discharge. □ *J Clin Med*. 2021;10(13):2945.
- 20. Latronico N, Peli E, Calza S, et al. Physical, cognitive and mental health outcomes in 1-year survivors of COVID-19-associated ARDS [published online ahead of print, 2021 Sep 29]. *Thorax*. 2021;thoraxjnl-2021-218064.
- 21. Dowdy DW, Eid MP, Dennison CR, et al. Quality of life after acute respiratory distress syndrome: a meta-analysis. ☐ *Intensive Care Med.* 2006;32(8):1115-1124.
- 22. Parry SM, Nalamalapu SR, Nunna K, et al. Six-Minute Walk Distance After Critical Illness: A Systematic Review and Meta-Analysis. ☐ *J Intensive Care Med.* 2021;36(3):343-
- 23. Whitaker M, Elliott J, Chadeau-Hyam M et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people medRxiv 2021.06.28.21259452; doi: https://doi.org/10.1101/2021.06.28.2125945
- 24. Blomberg B, Mohn KG, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients.

 [Nat Med. 2021;27(9):1607-1613]
- 25. Wynberg E, van Willigen HDG, Dijkstra M, et al. Evolution of COVID-19 symptoms during the first 12 months after illness onset [published online ahead of print, 2021 Sep 2]. Clin Infect Dis. 2021;ciab759.
- 26. Thompson EJ, Williams DM, Walker AJ et al. Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK. medRxiv□2021.06.24.21259277;□doi:□https://doi.org/10.1101/2021.06.24.21259277
- 27. UK Office of National Statistics COVID-
- 19 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsan ddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectioninth euk/2december2021. Accessed 6 December, 2021.
- 28. Boscolo-Rizzo, P, □ Guida, F, □ Polesel, J, et □ al. □ Sequelae in adults at 12 months after mild-to-moderate coronavirus disease 2019 (COVID-19). □ *Int Forum Allergy Rhinol*. □ 2021; □ 11: □ 1685–□ 1688.20 (PMC296319).

- 29. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med.* 2021; **27**(4):626-631.
- 30. Ghosn L, Chaimani A, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. *Cochrane Database Syst Rev.* 2021; **3**(3):CD013881.
- 31. Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. *Nat Med.* 2021; **27**(10):1752-1760.
- 32. Evans RA, Singh SJ. Minimum important difference of the incremental shuttle walk test distance in patients with COPD. *Thorax*. 2019; **74**(10):994-995.
- 33. Nolan CM, Delogu V, Maddocks M, et al. Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study. *Thorax* 2018; **73**(7):680-682.
- 34. Parreira VF, Janaudis-Ferreira T, Evans RA, Mathur S, Goldstein RS, Brooks D. Measurement properties of the incremental shuttle walk test, a systematic review. *Chest*. 2014; **145**(6):1357-1369. doi:10.1378/chest.13-2071
- 35. Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: Interim Guidance on Rehabilitation in the Hospital and Post-Hospital Phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force. *Eur Respir J.* 2020; **56**(6):2002197. doi:10.1183/13993003.02197-2020
- 36. Martin A, Naunton M, Kosari S, Peterson G, Thomas J, Christenson JK. Treatment Guidelines for PTSD: A Systematic Review. *J Clin Med.* 2021; **10**(18):4175.
- 37. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med*. 2021; **384**(11):989.
- 38. Docherty AB, Mulholland RH, Lone NI, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. *Lancet Respir Med.* 2021;9(7):773-785

Tables and Figures

Main manuscript

Tables

Table 1. Individual and hospital admission characteristics for the participants who had a five-

month visit, a one-year visit, and both visits.

Table 2. A comparison of the change between five-months and one-year post-discharge in

patient reported outcome measures including mental health, physical function, cognitive

impairment, and organ function

Table 3. A comparison of the change in patient reported outcome measures including mental

health, physical function, cognitive impairment, and organ function between five-month and

one-year sub-grouped by the four 'severity' cluster phenotypes

Figures

Figure 1. Consort diagram of participants

Figure 2. Four panel plot demonstrating patients perceived recovery at one year a) compared

with five months, b) risk factors for being less likely to recover, c) compared by the four

clusters d) compared to health-related quality of life (assessed by the EQ5D-5L Utility Index)

Figure 3. Volcano plots representing multinomial regression association results for

comparison of 368 proteins between a) clusters 1 (very severe) and 4 (mild), b) clusters 2

(severe) and 4 (mild) and c) clusters 3 (moderate) and 4 (mild). The red horizontal line

represents an unadjusted P<0.05 threshold. Proteins that were significantly over-expressed

(compared to the reference cluster 4) after FDR adjustment are indicated in red and those

29

significantly under-expressed are indicated in black, FDR cut off used was 0.1.

Figure 4. A comparison between the four 'severity' cluster phenotypes of health-related quality of life, disability, fatigue and breathlessness across pre-hospitalisation, five-months and one-year after hospital discharge.

Supplement Tables and Figures

- Table S1. Tier 2 outcome measures.
- Table S2. Methods and thresholds for processing of variables and outcome measures used in the current analysis.
- Table S3. Comparison of individual and admission characteristics, and patient-perceived recovery between the one-year visit attendees and non-attendees for participants discharged between February 2020 June 2020.
- Table S4. Comparison between imputed and non-imputed logistic regression of predictors of failure to recover at 1-year (multi-variable and multi-level).
- Table S5. Cluster medoids and characteristics
- Table S6. Comparison of participant demographics, clinical characteristics, and admission characteristics stratified by the four clinical recovery clusters.
- Table S7: Multinomial logistic regression of clinical characteristics against cluster membership (mild cluster as reference) for participants with plasma proteomic data.
- Table S8. Comparison of plasma proteomics between a) cluster 1 (very severe) and cluster 4 (mild), b) cluster 2 (severe) and cluster 4 (mild) and c) cluster 3 (moderate) and cluster 4 (mild). Multinomial regression results with unadjusted P<0.05 are presented.
- Table S9. Ongoing symptoms recorded at five-months and one-year post-discharge from hospital
- Table S10. Patient reported outcomes, physiological and biochemical tests stratified by patient perceived recovery outcomes at five-months and one-year visits a) paired data and b) unpaired data.
- Table S11. A comparison between the four clinical recovery phenotypes of health-related quality of life, disability, fatigue and breathlessness across pre-hospitalisation, and five-months and one-year post-discharge
- Figure S1. A comparison of participant-perceived recovery between five months and oneyear
- Figure S2. Clusters of mental, cognitive, and physical health impairments at five-months
- Figure S3. Figure S4. Characteristics associated with the four 'recovery' clusters

Figure S4. Estimation plots for the features significantly upregulated when comparing cluster 1 (very severe) to cluster 4 (mild) (panels a-m) and when comparing cluster 3 (moderate) to cluster 4 (mild) (panels n and o).

Figure S5. Health-related quality of life, disability, and symptoms across the four 'recovery' clusters assessed for pre-hospitalisation (patient estimated), and at five-months and one-year post-discharge (individual complete data for all three time-points)

Table 1. Individual and hospital admission characteristics for the participants who had a five-month visit, a one-year visit, and both visits.

	Complete five-month visit	Complete one-year visit	Completed both visits
Total N (%)	2320 (100·0)	924 (100·0)	807 (100.0)
Age at admission, years*	58.0 (12.6)	58-9 (12-5)	58.7 (12.5)
Female Sex at birth¶	855 (39·0)	319 (35·8)	279 (35-6)
Missing data	127	33	23
Ethnicity¶			
White	1685 (75.4)	681 (74-7)	596 (74-5)
South Asian	262 (11.7)	102 (11·2)	94 (11.8)
Black	154 (6.9)	68 (7.5)	57 (7.1)
Mixed	46 (2·1)	19 (2·1)	18 (2·2)
Other	87 (3.9)	42 (4.6)	35 (4.4)
Missing data	86	12	7
Pre-illness Occupation¶			
Full- or Part-time Employment	1053 (55.5)	493 (58-9)	460 (59·7)
Other occupation status	846 (44-5)	344 (41·1)	311 (40-3)
Missing data	421	87	36
Health-care worker¶	344 (16·2)	163 (19·0)	153 (20-4)
Missing data	203	67	58
Index of Multiple Deprivation (IMD)¶			
1 (most deprived)	517 (22-6)	187 (20-4)	163 (20.4)
2	533 (23·3)	186 (20·3)	163 (20-4)
3	404 (17·7)	175 (19·1)	155 (19-4)
`4	396 (17·3)	160 (17.5)	137 (17-2)
5 (least deprived)	438 (19·1)	207 (22.6)	180 (22-6)
Missing data	32	9	9
BMI †	31-2 (27-7 - 36-1)	31.5 (27.7 - 35.8)	31.5 (27.7 - 35.7)
$< 30 \text{ kg/m}^2 \P$	840 (41·1)	349 (40·3)	316 (41-2)
$\geq 30 \text{ kg/m}^2 \P$	1204 (58·9)	517 (59.7)	451 (58-8)
Missing data	276	58	40
Smoking status¶			
Never	1085 (54-7)	429 (53-2)	350 (52·8)
Ex-smoker	864 (43.5)	369 (45.7)	301 (45-4)
Current smoker	36 (1.8)	9 (1·1)	12 (1.8)
Missing data	335	117	144
WHO clinical progression scale¶			
WHO – class 3-4	385 (16-9)	171 (18.6)	145 (18-0)
WHO – class 5	959 (42-2)	342 (37·1)	299 (37-1)
WHO – class 6	517 (22-7)	167 (18·1)	139 (17-2)
WHO – class 7-9	412 (18·1)	241 (26-2)	224 (27-8)
Missing data	47	< 5	0
Comorbidities¶			
Median number of comorbidities †	2·0 (0·0 to 3·0)	2·0 (0·0 to 3·0)	2·0 (0·0 to 3·0)

0	642 (27.7)	251 (27-2)	213 (26-4)
1	468 (20·2)	172 (18-6)	154 (19·1)
≥2	1210 (52-2)	501 (54-2)	440 (54·5)
Cardiovascular	1027 (44-3)	425 (46.0)	375 (46·5)
Renal and endocrine	250 (10·8)	100 (10-8)	89 (11-0)
Respiratory	611 (26·3)	235 (25.4)	215 (26·6)
Type 2 diabetes	451 (19·4)	179 (19-4)	163 (20-2)
Neuro-psychiatric	465 (20.0)	171 (18-5)	149 (18·5)
Admission duration, days	13.9 (18.2)	17.0 (24.7)	17.8 (22.1)
Positive SARS-CoV-2 PCR¶	1916 (92.4)	796 (90-8)	700 (90-6)
Missing data	246	47	34
Systemic steroids¶	1173 (54-2)	251 (29·8)	226 (30-2)
Missing data	157	81	59
Antibiotic therapy¶	1769 (79-5)	746 (84.5)	660 (84.5)
Missing data	96	41	26
Therapeutic dose anti-coagulation¶§	941 (43-4)	320 (37.5)	282 (37·3)
Missing data	154	71	51

^{¶ =} Number (%) with positive response, *Mean [SD], †Median [IQR]. Percentages are calculated by category after exclusion of missing data for that variable. N= Number. WHO classes are as follows: 3–4 = no continuous supplemental oxygen needed; 5 = continuous supplemental oxygen only; 6 = continuous or bi-level positive airway pressure ventilation or high-flow nasal oxygen; and 7–9 = invasive mechanical ventilation or other organ support. BMI = body-mass index. PCR= Polymerase Chain Reaction. §Therapeutic dose anticoagulation; does not include intermediate doses which were not recorded.

a) A comparison of patient-perceived recovery at five-months and one-year (unpaired)

		I	ive-month visit		One-year visit						
	Total N (5-months)	Recovered	Not sure	Not recovered	p	Total N (1-year)	Recovered	Not sure	Not recovered	p	
Total N (%) All participants	1965 (100.0)	501 (25.5)	385 (19-6)	1079 (54-9)	-	804 (100.0)	232 (28-9)	180 (22-4)	392 (48-8)	-	
Total N (%) Paired data	590 (100.0)	151 (25.6)	326 (55·3)	113 (19-2)	-	590 (100.0)	168 (28-5)	284 (48-1)	138 (23-4)	-	

b) Patient reported outcome measures, physical function and organ function at five months stratified by patient-perceived recovery, and compared at one-year (paired data)

	Five-month vis	it – stratified by pa months, n	tient perceived recov =1965	Paired data at five-month and one-year visits, n=807						
	Recovered	Not sure	Not recovered	P	N pairs with available data	Five-months	One-year	p		
Total n (%)	501 (25.5)	385 (19-6)	1079 (54-9)	N/A	% recovered n=590	151 (25.6)	168 (28-5)	0.118		
Time to review from discharge, days †	166 (127- 191)	165 (122 - 191)	157 (119 - 189)	0.040	807	178 (156 - 197)	384 (359-409)	< 0.001		
BMI †	29-4 (26-6-33-5)	31.5 (28.0-36.3)	31.6 (28.0-36.4)	<0.001	602	30.7 (27.3-35.0)	31-1 (27-5-35-5)	< 0.001		
$< 30 \text{ kg/m}^2$	230 (54-5)	131 (40·2)	360 (38-8)	<0.001	602	275 (45.7)	255 (42-4)	0.021		
$\geq 30 \text{ kg/m}^2$	192 (45·5)	195 (59.8)	568 (61-2)			327 (54-3)	347 (57-6)			
Any symptom at time point¶	415 (83.0)	369 (95.8)	1066 (99.0)	<0.001	619	580 (93.7)	584 (94-3)	0.671		
Median number of symptoms †	3 (1 - 7)	8 (4 - 15)	14 (8 - 20)	<0.001	619	9 (4 - 16)	9 (4 - 17)	0.010		
Fatigue VAS †	0.0 (0.0 - 2.0)	2.0 (0.0 - 5.0)	5.0 (2.0 - 8.0)	< 0.001	521	3.0 (0.0 - 6.0)	3.0 (0.0 - 6.0)	0.090		
Breathlessness VAS †	0.0 (0.0 - 1.0)	1.5 (0.0 - 4.0)	4.0 (1.0 - 6.0)	< 0.001	524	2.0 (0.0 - 5.0)	2.0 (0.0 - 5.0)	0.052		
Anxiety (GAD7 >8)¶	53 (11·3)	81 (22-6)	339 (33-4)	<0.001	684	164 (24.0)	147 (21.5)	0.125		
Depression (PHQ-9 ≥10)¶	47 (9.9)	96 (26-7)	426 (42.0)	<0.001	680	181 (26.6)	169 (24.9)	0.246		
PTSD (PCL-5 ≥38)¶	18 (3.8)	34 (9.5)	202 (20-0)	<0.001	680	83 (12-2)	68 (10-0)	0.055		
Dyspnoea-12 score*	2.1 (4.8)	5.1 (7.1)	8.9 (8.8)	<0.001	702	6.0 (8.1)	5.5 (7.7)	0.040		
FACIT fatigue subscale score*	43.6 (8.8)	36.5 (11.2)	29-1 (12-8)	<0.001	679	35.7 (12.9)	36.3 (12.5)	0.070		

BPI severity*	9.2 (10.1)	12.0 (9.5)	15.2 (10.0)	<0.001	455	12.9 (9.7)	12.8 (9.8)	0.897
BPI interference*	11-2 (16-4)	17.6 (17.3)	24.8 (19.8)	<0.001	432	19.6 (19.1)	19.2 (17.8)	0.533
SPPB ≤10¶	181 (38-9)	166 (46.0)	582 (58·8)	<0.001	685	318 (46-4)	309 (45·1)	0.531
ISWT distance, m*	487-6 (274-7)	431-4 (242-3)	384-6 (249-4)	<0.001	509	453-6 (262-8)	468-2 (267-8)	0.017
ISWT % predicted*	63.5 (30.7)	57-8 (28-1)	52.5 (28.7)	<0.001	429	60-1 (29-4)	61.2 (28.7)	0.215
Rockwood CFS ≥5¶	9 (2.0)	17 (4.9)	81 (8.2)	<0.001	651	41 (6.3)	46 (7.1)	0.532
MoCA <23¶	66 (16·5)	39 (12-4)	147 (15·8)	0.257	623	89 (14-3)	62 (10-0)	0.001
MoCA (adjusted) <23¶	57 (14-3)	36 (11.4)	125 (13-4)	0.520	623	72 (11-6)	55 (8.8)	0.034
FEV1 <80% predicted¶	43 (21-4)	43 (27-7)	131 (27-9)	0.196	287	67 (23-3)	63 (22-0)	0.643
FVC <80% predicted¶	40 (19-9)	33 (21-4)	155 (33·2)	<0.001	281	79 (28-1)	63 (22-4)	0.018
FEV1/FVC <70%¶	25 (8.8)	23 (10-6)	49 (7.5)	0.352	311	25 (8.0)	28 (9.0)	0.606
BNP \geq 100 ng/L or Pr-NT-BNP \geq 400 ng/L¶	27 (8.7)	24 (10·3)	35 (5·2)	0.014	335	30 (9.0)	29 (8.7)	1.000
HbA1C ≥6·0% (DCCT/NGSP)¶	6.1 (1.2)	6.2 (1.3)	6.2 (1.3)	0.598	399	140 (35·1)	130 (32.6)	0.212
eGFR < 60 ml/min/1·73 m ² ¶	49 (12.0)	35 (11·3)	101 (11-4)	0.943	564	73 (12-9)	79 (14-0)	0.451
D Dimers >250 ng/ml¶	141 (40.8)	110 (42·3)	257 (35·8)	0.103	416	159 (38-2)	149 (35.8)	0.289
CRP >5 mg/L¶	83 (20.9)	75 (23.9)	239 (27·1)	0.052	557	126 (22.6)	133 (23.9)	0.515
Fibrinogen (g/L)*	3.5 (0.9)	3.6 (0.8)	3.6 (0.9)	0.341	379	3.5 (0.9)	3.5 (0.9)	0.972
Ferritin (µg/L)*	136-3 (149-7)	145-3 (150-6)	140-1 (166-4)	0.787	449	141-2 (150-6)	129-1 (136-2)	<0.001
EQ5DL utility index †	0.9 (0.8 - 1.0)	0.8 (0.7 - 0.9)	0.7 (0.5 - 0.8)	< 0.001	585	0.7 (0.6 - 0.9)	0.8 (0.6 - 0.9)	0.954
WG-SS-SCo†	0.0 (0.0 - 2.0)	2.0 (0.5 - 3.0)	3.0 (1.0 - 8.0)	< 0.001	548	2.0 (0.0 - 4.0)	2.0 (0.0 - 4.0)	0.731
		1	1					

^{¶ =} Number (%) with positive response, *Mean [SD], †Median [IQR]. Percentages are calculated by category after exclusion of missing data for that variable. P values across patient perceived recovery were calculated using a chi-squared test when testing for differences between proportions, ANOVA F-test for normally distributed continuous data and Kruskal Wallis for non-normally distributed continuous data. For paired data, P values for McNemar's Chi-squared test with continuity correction for binary variables, P values for McNemar's Chi-squared test when there are more than two levels, P values for Wilcoxon signed-rank test for variables summarised as median [IQR] are presented and P values for paired t-test for variables summarised as mean [SD] are presented. VAS = Visual Analogue Scale, GAD7 = Generalized Anxiety Disorder 7-item scale. PHQ-9 = Patient Health Questionnaire-9. PCL-5 = Post Traumatic Stress Disorder Checklist. FACIT fatigue = Functional Assessment of Chronic Illness Therapy Fatigue Scale. BPI = Brief Pain Inventory, EQ5D-5L UI = Utility Index, WG-SS-SCo = Washington Group Short Set of Functioning Severity Continuum, SPPB = short physical performance battery. ISWT = incremental shuttle walk test. CFS = Clinical Frailty Scale. MoCA = Montreal Cognitive Assessment. Adjusted MoCA = MoCA adjusted for education. FEV1 = Forced Expiratory Volume in the first second. FVC = forced vital capacity. TLCO = transfer capacity of the lung for carbon monoxide. KCO = carbon monoxide transfer coefficient. BNP = brain natriuretic peptide. Pro-NT-BNP = N-terminal BNP. HbA1C = glycated haemoglobin. DCCT/NGSP = Diabetes Control and Complications Trial/National Glycohemoglobin Standardization Program. eGFR = estimated glomerular filtration rate. CRP = C-reactive protein.

Table 3. A comparison of the change in patient reported outcome measures including mental health, physical function, cognitive impairment, and organ function between five-months and one-year sub-grouped by the four 'severity' clinical phenotypes

	1: Very severe					2: Severe				3: Moderate / Cognitive				4: Mild			
	N pairs	5-m	1-year	p	N pairs	5-m	1-year	p	N pairs	5-m	1-year	p	N pairs	5-m	1-year	p	
Time to review, days †	99	174	393	-	176	176	386	-	75	174	378	-	252	180	388	-	
PROMS																	
Symptom count †	80	20	20	0.302	141	13	13	0.107	61	7	9	0.224	188	4	4	0.754	
Anxiety (GAD7 ≥8)¶	88	93.2	70-5	<0.001	152	24.3	23.0	0.888	70	5.7	14.3	0.077	225	1.3	3.6	0.131	
Depression (PHQ-9 ≥ 10)¶	87	96.6	80-5	0.001	152	32.2	27.0	0.280	70	2.9	7.1	0.371	225	0.9	3.1	0.182	
PTSD (PCL-5 ≥ 38)¶	88	65.9	47-7	0.005	152	3.3	6.6	0.228	68	0.0	1.5	NA	223	0.0	0.4	NA	
Dyspnoea-12 score*	89	18-0	15.2	0.003	167	6.5	5.7	0.107	67	2.9	4	0.066	238	1.5	1.4	0.639	
FACIT fatigue subscale score*	88	17-4	21.8	<0.001	152	30-6	33.5	<0.001	69	42.0	39-1	0.005	225	45.8	45.0	0.043	
BPI severity*	69	21-2	21.4	0.832	110	13-2	12.5	0.350	40	12-2	10.8	0.416	135	8-1	8.0	0.904	
BPI interference*	69	40-0	36-2	0.091	104	21.3	18-5	0.074	40	14-2	15.6	0.642	126	7.0	8-7	0.112	
Physical performance																	
SPPB ≤10¶	86	68-6	69-8	1.000	164	48-8	46.3	0.671	70	80.0	70-0	0.096	239	23.0	26-4	0.341	
ISWT distance, m*	65	308	332	0.136	122	454	476	0.056	45	349	355	0.724	172	552	571	0.070	
ISWT % predicted*	58	40-7	44-4	0.143	105	59.9	62.4	0.107	39	56.5	57-3	0.721	138	71.6	72-4	0.623	
CFS≥5¶	79	24-1	15-2	0.146	150	2.0	3.3	0.617	63	4.8	14.3	0.077	213	0.9	0.5	1.000	
Cognitive impairment																	
MOCA <23¶	88	22.7	15-9	0.149	161	5.6	5.6	1.000	62	59.7	32.3	<0.001	232	3.9	3.0	0.752	
MOCA (corrected) <23¶	88	20-5	13.6	0.114	161	3.7	4.3	1.000	62	53-2	29.0	0.002	232	1.7	2.6	0.683	
Organ function																	
FEV1 % predicted*	28	89-4	91.2	0.598	61	96-1	95.3	0.532	33	97.9	96.4	0.524	86	92.8	93-4	0.537	
FEV1 % <80% predicted¶	28	35.7	25.0	0.248	61	21.3	18.0	0.724	33	21.2	27.3	0.724	86	18-6	22.1	0.547	
FVC % predicted*	27	83-7	87-6	0.073	60	93.7	97.0	0.015	33	97.0	96.8	0.955	86	92.8	93.4	0.730	
FVC % <80% predicted¶	27	51.9	37-0	0.134	60	25	18-3	0.221	33	36-4	27.3	0.450	86	22.1	23.3	1.000	
FEV1/FVC <0·7¶	29	6.9	3.4	1.000	65	4.6	10.8	0.133	34	14.7	17.6	1.000	99	6.1	5.1	1.000	

BNP≥100 ng/L or Pro- NT-BNP≥400 ng/L¶	43	14	9.3	0.617	69	2.9	2.9	1.000	32	15-6	21.9	0.480	89	6.7	5.6	1.000
HbA1C ≥6·0% (DCCT/NGSP)¶	51	45-1	41.2	0.724	86	26.7	27.9	1.000	35	31-4	31.4	1.000	126	35.7	31.7	0.267
eGFR <60 ml/min/1·73 m²¶	74	10.8	20.3	0.023	123	10-6	9.8	1.000	52	19-2	25	0.371	168	13.7	13.7	1.000
D Dimers >250ng/ml ¶	50	32	32	1.000	88	30-7	30-7	1.000	38	42.1	42.1	1.000	141	28-4	27.7	1.000
CRP >5 mg/L¶	73	34-2	38-4	0.505	118	30-5	27-1	0-453	52	7.7	21-2	0.046	165	13.9	14.5	1.000
Fibrinogen (g/L)*	44	3.5	3.7	0.043	83	3.6	3.5	0-257	32	3.7	3.9	0.264	118	3.2	3.3	0.480
Ferritin (µg/L)*	55	125-8	108-7	0.046	99	142.6	127-7	<0.001	37	125-8	130-3	0.688	129	145.8	140-3	0.284

Number (%) ¶ = % of category with positive response *Mean [SD], † median [IQR]. Missing not included in %. P values for McNemar's Chi-squared test with continuity correction for binary variables, P values for McNemar's Chi-squared test when there are more than two levels, P values for Wilcoxon signed-rank test for variables summarised as median [IQR] are presented and P values for paired t-test for variables summarised as mean [SD] are presented. Symptom count denominator n=XX. PROMS = Patients reported outcomes. GAD7 = Generalized Anxiety Disorder 7-item scale. PHQ-9 = Patient Health Questionnaire-9. PCL-5 = Post Traumatic Stress Disorder Checklist. FACIT fatigue = Functional Assessment of Chronic Illness Therapy Fatigue Scale. BPI = Brief Pain Inventory. SPPB = short physical performance battery. ISWT = incremental shuttle walk test. CFS = Clinical Frailty Scale. MoCA = Montreal Cognitive Assessment. Adjusted MoCA = MoCA adjusted for education. FEV1 = Forced Expiratory Volume in the first second. FVC = forced vital capacity. TLCO = transfer capacity of the lung for carbon monoxide. KCO = carbon monoxide transfer coefficient. BNP = brain natriuretic peptide. NT-BNP = N-terminal BNP. HbA1C = glycated haemoglobin. DCCT/NGSP = Diabetes Control and Complications Trial/National Glycohemoglobin Standardization Program. eGFR = estimated glomerular filtration rate. CRP = C-reactive protein.

Figure 1. Consort diagram of participants

Analogue Scale




Figure 1 Legend. GAD-7 = Generalized Anxiety Disorder 7-item scale. PHQ-9 = Patient Health Questionnaire-9. PCL-5 Post Traumatic Stress Disorder Checklist. FACIT Fatigue Scale = Functional Assessment of Chronic Illness Therapy Fatigue Scale. SPPB=short physical performance battery. MoCA = Montreal Cognitive Assessment. WG-SS-SCo = Washington Group Short Set of Functioning Severity Continuum. VAS = Visual

Figure 2. Four panel plot demonstrating patients perceived recovery at one year a) compared with five months, b) risk factors for being less likely to recover, c) compared by the four clusters d) compared to health-related quality of life (assessed by the EQ5D-5L Utility Index)





Figure 2 Legend.

BMI: Body Mass Index, WHO: World Health Organisation, WHO clinical progression scale classes are as follows: 3–4 = no continuous supplemental oxygen needed; 5 = continuous supplemental oxygen only; 6 = continuous positive airway pressure or bi-level positive pressure ventilation or high-flow nasal oxygen; and 7–9 = invasive mechanical ventilation or other organ support. The forest plot of the patient and admission characteristics associated with patient perceived recovery at one-year used multivariable logistic regression and multiple imputation. EQ5D-5L pre-COVID was retrospectively completed by participants.

Figure 3. Volcano plots representing multinomial regression association results for comparison of 296 proteins between the four clinical phenotypes



Coefficient





Figure 3 Legend. Volcano plots representing multinomial regression association results, corrected for age, BMI and number of comorbidities, comparing 296 proteins between a) clusters 1 (very severe) and 4 (mild), b) cluster 2 (severe) and cluster 4 (mild) and c) cluster 3 (moderate) and cluster 4 (mild). The red horizontal line represents an unadjusted P<0.05 threshold. Proteins that were significantly differentially-expressed (compared to the reference cluster 4) after False Detection Rate (FDR) adjustment are indicated in red, FDR cut off used was 0.1.

Figure 4. Health-related quality of life, disability, and symptoms across the four 'severity' clusters assessed for pre-hospitalisation (patient estimated), five-months and one-year post-discharge.


a) Health-related quality of life assessed by the EQ5D-5L utility index

Patient symptom cluster by EQ5DL utility index Each group: Pre-COVID, 5 months, 1 year | Numbers are counts




b) Disability assessed by the Washington Group Short Set of Functioning Severity Continuum (WG-SS-SCo)

Patient symptom cluster by WG-SS-SCo Each group: Pre-COVID, 5 months, 1 year | Numbers are counts



c) Fatigue severity in the last 24 hrs assessed using a Visual Analogue Scale 0-10

Patient symptom cluster by VAS Fatigue Each group: Pre-COVID, 5 months, 1 year | Numbers are counts



d) Breathlessness severity in the last 24 hrs assessed using a Visual Analogue Scale 0-10

Patient symptom cluster by VAS Breathlessness

Each group: Pre-COVID, 5 months, 1 year | Numbers are counts




Figure 4. Legend

Red cluster – very severe mental/ physical health impairment Blue cluster – severe mental/ physical health impairment Green cluster – moderate physical / cognitive impairment Purple cluster – mild mental/ physical health impairment Pre-hospital health status assessed retrospectively